BioXcel Therapeutics, Inc. (BTAI)
BTAI Stock Price Chart
Explore BioXcel Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze BTAI price movements and trends.
BTAI Company Profile
Discover essential business fundamentals and corporate details for BioXcel Therapeutics, Inc. (BTAI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Mar 2018
Employees
37.00
CEO
Vimal D. Mehta
Description
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
BTAI Financial Timeline
Browse a chronological timeline of BioXcel Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$1.54, while revenue estimate is $220.00K.
Earnings released on 12 Aug 2025
EPS came in at -$2.45 falling short of the estimated -$2.30 by -6.52%, while revenue for the quarter reached $120.00K , missing expectations by -53.40%.
Earnings released on 12 May 2025
EPS came in at -$1.50 surpassing the estimated -$2.72 by +44.85%, while revenue for the quarter reached $168.00K , missing expectations by -52.00%.
Earnings released on 27 Mar 2025
EPS came in at -$3.57 surpassing the estimated -$4.36 by +18.12%, while revenue for the quarter reached $366.00K , missing expectations by -49.04%.
Stock split effective on 10 Feb 2025
Shares were split 1 : 16 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2024
EPS came in at -$5.12 surpassing the estimated -$8.00 by +36.00%, while revenue for the quarter reached $214.00K , missing expectations by -82.77%.
Earnings released on 6 Aug 2024
EPS came in at -$3.36 surpassing the estimated -$12.16 by +72.37%, while revenue for the quarter reached $1.10M , beating expectations by +18.71%.
Earnings released on 9 May 2024
EPS came in at -$13.92 falling short of the estimated -$10.88 by -27.94%, while revenue for the quarter reached $582.00K , beating expectations by +29.33%.
Earnings released on 12 Mar 2024
EPS came in at -$12.16 surpassing the estimated -$15.68 by +22.45%, while revenue for the quarter reached $376.00K , missing expectations by -47.04%.
Earnings released on 14 Nov 2023
EPS came in at -$27.52 falling short of the estimated -$20.64 by -33.33%, while revenue for the quarter reached $341.00K , missing expectations by -53.29%.
Earnings released on 14 Aug 2023
EPS came in at -$29.28 falling short of the estimated -$27.52 by -6.40%, while revenue for the quarter reached $457.00K , beating expectations by +1.56%.
Earnings released on 8 May 2023
EPS came in at -$29.44 falling short of the estimated -$24.96 by -17.95%, while revenue for the quarter reached $206.00K , missing expectations by -58.80%.
Earnings released on 9 Mar 2023
EPS came in at -$31.20 falling short of the estimated -$23.84 by -30.87%, while revenue for the quarter reached $238.00K , missing expectations by -80.96%.
Earnings released on 10 Nov 2022
EPS came in at -$23.84 falling short of the estimated -$21.44 by -11.19%, while revenue for the quarter reached $137.00K , missing expectations by -86.37%.
Earnings released on 9 Aug 2022
EPS came in at -$21.60 falling short of the estimated -$19.20 by -12.50%.
Earnings released on 9 May 2022
EPS came in at -$17.92 surpassing the estimated -$19.36 by +7.44%.
Earnings released on 10 Mar 2022
EPS came in at -$14.88 surpassing the estimated -$18.88 by +21.19%.
Earnings released on 10 Nov 2021
EPS came in at -$15.36 surpassing the estimated -$17.28 by +11.11%.
Earnings released on 10 Aug 2021
EPS came in at -$17.76 falling short of the estimated -$16.48 by -7.77%.
Earnings released on 10 May 2021
EPS came in at -$17.28 falling short of the estimated -$14.24 by -21.35%.
Earnings released on 11 Mar 2021
EPS came in at -$13.92 matching the estimated -$13.92, while revenue for the quarter reached $0.02 .
Earnings released on 12 Nov 2020
EPS came in at -$17.12 falling short of the estimated -$12.80 by -33.75%, while revenue for the quarter reached $0.01 .
BTAI Stock Performance
Access detailed BTAI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.